Optimizing Bispecific Antibody Therapy in Relapsed-Refractory Multiple Myeloma: Real-World Evidence and Implementation Strategies
An expert explains that real-world data affirm the strong efficacy and manageable safety of bispecific antibodies like teclistamab in relapsed/refractory multiple myeloma—including in patients beyond trial eligibility—and that combining agents such as teclistamab and talquetamab offers promising options for high-risk cases; optimizing safety through step-up dosing, infection prophylaxis, and supportive care enables broader outpatient use, while ongoing research aims to expand their role earlier in treatment and explore stopping strategies after sustained minimal residual disease negativity to personalize and improve long-term patient outcomes.
EP. 1: Understanding REALiTEC: Real-World Insights on BCMA Bispecifics
August 4th 2025An expert explains that real-world data from the REALiTEC study shows teclistamab remains highly effective in relapsed/refractory multiple myeloma—even among patients ineligible for clinical trials—demonstrating strong response rates, encouraging survival outcomes, and reinforcing the importance of therapy sequencing and broad access to bispecific antibodies in everyday clinical practice.
EP. 2: Teclistamab in Practice: Real-World Efficacy and Infection Risks
August 11th 2025An expert explains that teclistamab has proven to be a highly effective and well-tolerated therapy for relapsed/refractory multiple myeloma in real-world settings, with outcomes mirroring clinical trials and improved infection management strategies enhancing its safety and accessibility for a broader range of patients.
EP. 3: Exploring Bispecific Combinations: REDIRECTT ASCO 2025 Highlights
August 18th 2025An expert discusses that combining the bispecific antibodies teclistamab and talquetamab has shown promising efficacy and manageable toxicity in heavily pretreated multiple myeloma patients—including those with extramedullary disease—offering a compelling dual-targeted option for high-risk cases while allowing flexibility in sequencing for slower-progressing disease.
